SMS Pharma Peer Comparison

NSE: SMSPHARMA | BSE: 532815

₹442.95

₹29.20 (7.06%)

As on 18-Sep-2026IST

Market cap

₹4,148 Cr

Revenue (TTM)

₹898 Cr

P/E Ratio

40.5

P/B Ratio

5.1

Div. Yield

0.1 %

Edit

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	4,148	33,911	29,031	28,149	27,692
Revenue (₹ Cr)	898	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	89.48	414.00	288.22	387.35	-371.81
Net Margin (%)	9.86	11.23	14.79	26.01	-3.93
RoE (%)	13.52	8.38	29.77	25.18	-3.85
Price to Earnings	40.51	82.91	100.73	72.88	--
Price-To-Book	5.15	6.74	21.63	16.31	3.46

Income Statement (₹ Cr)

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	897.79	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	907.29	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	724.93	2,792.00	1,485.56	919.25	8,195.15
EBITDA	172.86	772.00	450.24	542.56	1,010.13
Depreciation	40.16	226.00	50.83	37.68	857.51
EBIT	132.70	546.00	399.41	504.88	152.62
Interest	22.74	217.00	40.84	3.77	342.73
Other Income	9.50	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	119.47	463.00	371.35	528.56	-162.68
Provision for Tax	29.99	49.00	83.14	141.21	209.13
Profit after Tax	89.48	414.00	288.22	387.35	-371.81

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	785.81	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	223.65	1,712.00	202.03	42.40	5,044.14
Current Liabilities	352.98	1,622.00	835.87	230.82	4,758.28
Total Liabilities	1,387.80	8,578.00	2,326.71	1,983.96	17,723.32

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	681.94	5,343.00	519.60	1,026.85	10,211.52
Current Assets	638.01	2,606.00	1,681.81	881.27	7,191.66
Total Assets	1,387.80	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	365.05	2,125.00	259.37	26.49	5,495.48
Net Current Assets	285.04	984.00	845.94	650.46	2,433.38
Contingent Liabilities	56.89	768.26	19.09	17.25	95.72

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	59.22	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-130.78	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	76.03	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	4.48	95.00	78.39	30.33	787.59

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	13.32	6.79	29.22	32.42	1.24
ROE (%)	13.52	8.38	29.77	25.18	-3.85
ROA (%)	7.12	4.94	24.77	21.93	-2.21
EBIT Margin (%)	14.78	15.32	20.63	34.54	1.66
Net Margin (%)	9.86	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	10.25	18.37	46.65	40.90	0.78
EBIT Growth (%)	21.59	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	28.31	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	29.81	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	25.98	13.47	144.31	26.03	0.33

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	40.51	85.10	99.18	72.88	-88.50
Price / Book Value	5.15	6.74	21.63	16.31	3.46
Dividend Yield (%)	0.09	0.00	0.09	0.07	0.00
EV/EBITDA	25.84	45.82	64.29	51.52	31.51
Market Cap (₹ Cr)	3,509.17	19,071.62	12,753.19	20,944.75	18,108.89

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.22	0.31	0.11	0.02	0.53
Short term debt to equity ratio	0.19	0.09	0.05	0.02	0.09
Current Ratio	1.81	1.61	2.01	3.82	1.51
Quick Ratio	0.81	1.06	1.14	2.82	0.87
Interest Coverage	6.25	3.13	10.09	141.16	0.53

	SMS Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	24.04	16.50	26.28	24.80	23.44
Asset Turnover	0.71	0.43	1.66	0.83	0.55
Receivable days	76.30	58.75	40.13	88.98	78.20
Inventory Days	115.77	75.82	60.29	56.04	93.30
Payable days	86.69	186.21	232.47	99.95	226.14
Cash Conversion Cycle	105.37	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.